LEBWOHL, M. G.; SUGARMAN, J. L.; GOLD, L. S.; LIN, T.; MARTIN, G. Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Severe Plaque Psoriasis: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 3, p. S29, 2019. DOI: 10.25251/skin.3.supp.29. Disponível em: https://jofskin.org/33014/index.php/skin/article/view/756. Acesso em: 3 jul. 2024.